EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Alteration of the Gut–Lung Axis After Severe COVID-19 Infection and Modulation Through Probiotics: A Randomized, Controlled Pilot Study

Angela Horvath, Hansjörg Habisch iD, Barbara Prietl, Verena Pfeifer, Irina Balazs iD, Gabor Kovacs, Vasile Foris iD, Nikolaus John, Daniela Kleinschek, Nicole Feldbacher, Henning Grønbæk, Holger Jon Møller und 3 weitere

Nutrients · 08.11.2024 · 16 (22) · 3840

DOI: 10.3390/nu16223840 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Nutrients, online erschienen am 08.11.2024. Verfasst von Angela Horvath und 14 weiteren Autor:innen. Beteiligte Einrichtung: Center for Biomarker Research in Medicine (CBmed), Division of Translational Precision Medicine, Division of Precision Medicine Technologies, 8010 Gr…. Hauptthemen laut MEDLINE: Probiotics, COVID-19, Gastrointestinal Microbiome, Lung. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 110 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Austrian Research Promotion Agency, FWF Austrian Science Fund, Integrative Metabolism Research Center Graz.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The gut–lung axis could be a potential therapeutic target for improving post-acute COVID-19 symptoms, and probiotics have been proposed as possible modulators.

Aim

We conducted a pilot study to understand alterations in the gut–lung axis and to explore the effects of a probiotic in post-acute COVID-19 disease.

Methods

We included patients after severe COVID-19 disease (sCOV, n = 21) in a randomized, placebo-controlled trial to test the effect of a probiotic (Pro-Vi 5, Institute Allergosan, Graz, Austria) in a six-month intervention and used patients after mild disease (mCOV, n = 10) as controls, to compare the intestinal microbiome, metabolome, and patient-reported outcomes and biomarkers along the gut–lung axis at baseline and throughout probiotic intervention.

Results

Compared to mCOV patients, sCOV patients showed lower microbial richness, which was significantly improved by probiotic intervention. A reorganization of Ruminococcaceae and Lachnospiraceae taxa was observed in sCOV patients but remained unaffected by the intervention. Serum metabolome showed a dysregulation of lipoproteins in accordance with higher BMI and comorbidities in sCOV patients. HDL and LDL fractions/components were temporarily decreased in the probiotic group. Stool metabolome was altered at baseline in sCOV patients and an increase in L-DOPA after 3 months and butyrate after 6 months of intervention could be observed. Probiotics partially improved reduced quality of life and modulated altered immune responses in sCOV patients. Increased intestinal permeability at baseline remained unaffected.

Conclusion

The study provides evidence of long-term alterations of the gut–lung axis after severe COVID-19 infection and suggests that probiotics can modulate the biomarkers of the gut–lung axis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProbioticsCOVID-19Gastrointestinal MicrobiomeLungSARS-CoV-2HumansPilot ProjectsMaleFemaleMiddle AgedAgedMetabolomeAdultFecesBiomarkersSeverity of Illness Index

Stichwörter der Autor:innen

COVID-19gut microbiomegut–lung axisimmune phenotypingneutrophil functionprobioticsquality of life

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Center for Biomarker Research in Medicine (CBmed), Division of Translational Precision Medicine, Division of Precision Medicine Technologies, 8010 Graz, Austria.
  • Division for Gastroenterology and Hepatology, Department of Internal Medicine, Medical University of Graz, 8010 Graz, Austria.
  • Otto Loewi Research Center, Medicinal Chemistry, Medical University of Graz, 8010 Graz, Austria.
  • BioTechMed-Graz, 8010 Graz, Austria.
  • Division of Endocrinology and Diabetes, Department of Internal Medicine, Medical University of Graz, 8010 Graz, Austria.
  • Division of Pulmonology, Department of Internal Medicine, Medical University of Graz, 8010 Graz, Austria.

ORCID-Profile: Hansjörg Habisch, Irina Balazs, Vasile Foris, Tobias Madl, Vanessa Stadlbauer

Förderung

  • Austrian Research Promotion Agency
  • FWF Austrian Science Fund
  • Integrative Metabolism Research Center Graz
  • Austrian Infrastructure Program 2016/2017
  • Styrian Government (Zukunftsfonds, doc. fund program)
  • City of Graz
  • BioTechMed-Graz
  • Austrian Science Fund

Zitieren

APA

Horvath, A., Habisch, H., Prietl, B., Pfeifer, V., Balazs, I., Kovacs, G., Foris, V., John, N., Kleinschek, D., Feldbacher, N., Grønbæk, H., Møller, H. J., Žukauskaitė, K., Madl, T., & Stadlbauer, V. (2024). Alteration of the Gut–Lung Axis After Severe COVID-19 Infection and Modulation Through Probiotics: A Randomized, Controlled Pilot Study. Nutrients, 16(22), 3840. https://doi.org/10.3390/nu16223840

Vancouver

Horvath A, Habisch H, Prietl B, Pfeifer V, Balazs I, Kovacs G, et al. Alteration of the Gut–Lung Axis After Severe COVID-19 Infection and Modulation Through Probiotics: A Randomized, Controlled Pilot Study. Nutrients. 2024;16(22):3840. doi:10.3390/nu16223840

BibTeX
@article{Horvath2024,
  author = {Horvath, Angela and Habisch, Hansjörg and Prietl, Barbara and Pfeifer, Verena and Balazs, Irina and Kovacs, Gabor and Foris, Vasile and John, Nikolaus and Kleinschek, Daniela and Feldbacher, Nicole and Grønbæk, Henning and Møller, Holger Jon and Žukauskaitė, Kristina and Madl, Tobias and Stadlbauer, Vanessa},
  title = {Alteration of the Gut–Lung Axis After Severe COVID-19 Infection and Modulation Through Probiotics: A Randomized, Controlled Pilot Study},
  journal = {Nutrients},
  year = {2024},
  volume = {16},
  number = {22},
  pages = {3840},
  doi = {10.3390/nu16223840}
}
Kostenlos starten →